📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
143 announcements match the current filters (relevance ≥ 5).
Jubilant Pharmova Q3 Revenue Rises 17% to Rs 2,123 Cr; CDMO Growth Offsets Montreal Shutdown
Jubilant Pharmova reported a solid 17% YoY revenue growth in Q3 FY26, reaching Rs 2,123 crore, driven by a 49% surge in the CDMO Sterile Injectables segment. However, normalized PAT declined by 17% to Rs 86 crore, and EBITDA margins contracted to 14.5% due to a temporary remediation-related shutdown at the Montreal facility. The company's leverage improved with Net Debt/EBITDA falling to 1.3x from 1.5x in the previous quarter. Management expects margin recovery in Q4 as production has resumed at the Montreal site and new capacities ramp up.
Key Highlights
Revenue grew 17% YoY to Rs 2,123 Cr, while 9M FY26 revenue reached Rs 5,990 Cr (up 13%).
CDMO Sterile Injectables revenue jumped 49% YoY to Rs 457 Cr, supported by the new Line 3 in Spokane.
EBITDA margins contracted by 172 bps YoY to 14.5% due to Montreal facility shutdown and remediation costs.
Ruby-Fill installation base grew by 37% in 9M FY26, significantly outpacing the 21% growth in FY25.
Generics business remained profitable for the third consecutive quarter with 13% revenue growth.
👀 What to Watch
Investors should focus on the margin recovery trajectory in Q4 as the Montreal facility resumes operations and high-margin Radiopharma products scale. The strong top-line growth in CDMO and Radiopharma provides a positive long-term outlook despite temporary operational headwinds.
Jubilant Pharmova Q3 Standalone Net Profit Rises 24.5% YoY to ₹66 Million
Jubilant Pharmova reported a 20% YoY growth in standalone revenue to ₹673 million for the quarter ended December 31, 2025. Profit before tax from continuing operations saw a significant surge of 90% YoY, reaching ₹101 million, primarily driven by a sharp reduction in finance costs. The company successfully completed the slump sale of its API business to its subsidiary, Jubilant Biosys, on September 1, 2025, which is now reflected as discontinued operations. Total net profit for the quarter stood at ₹66 million, up from ₹53 million in the corresponding quarter of the previous year.
Key Highlights
Standalone revenue from operations increased 20% YoY to ₹673 million in Q3 FY26.
Profit before tax from continuing operations surged 90% YoY to ₹101 million.
Finance costs significantly decreased to ₹9 million from ₹33 million in the year-ago period.
The API business transfer was completed for a net asset value of ₹5,956 million on September 1, 2025.
Total comprehensive income for the period stood at ₹67 million versus ₹51 million YoY.
👀 What to Watch
Investors should view the sharp reduction in finance costs and the restructuring of the API business as positive steps toward operational efficiency. Monitor the consolidated results for a clearer picture of the group's overall growth trajectory post-restructuring.
Jubilant Ingrevia Q3 FY26: PAT at ₹47 Cr; Declares ₹2.5 Interim Dividend Amid Pricing Pressure
Jubilant Ingrevia reported a mixed Q3 FY26 with revenue of ₹1,051 crore, down 1% YoY, as strong volume growth was offset by global pricing pressures. While quarterly PAT fell 32% YoY to ₹47 crore due to a one-time exceptional labor code expense, 9M FY26 performance remains positive with EBITDA up 8% YoY. The company declared an interim dividend of ₹2.5 per share (250%) and highlighted a robust CDMO pipeline with a peak revenue potential of ₹3,500 crore. Management remains optimistic about Q4, citing the commissioning of the $300 million Agro-Innovator project.
Key Highlights
Q3 FY26 Revenue stood at ₹1,051 Cr, with EBITDA margins holding steady at 13% despite global pricing headwinds.
Board declared an interim dividend of 250% (₹2.5 per equity share) for the financial year 2025-26.
CDMO pipeline expanded to 100+ active opportunities with a peak annual revenue potential of ₹3,500 Cr.
The $300 million Agro-Innovator project is on track for Q4 FY26 commissioning with dispatches starting March 2026.
Specialty Chemicals segment maintained resilient margins above 25% despite price volatility in Pyridine and Picolines.
👀 What to Watch
Investors should focus on the upcoming commissioning of the Agro-Innovator project and the conversion of the ₹3,500 Cr CDMO pipeline as primary growth catalysts. While short-term pricing pressure persists, the company's volume growth and cost-efficiency measures provide a margin cushion.
Jubilant Ingrevia Q3 FY26: PAT Drops 32% to ₹47 Cr; Declares ₹2.5 Interim Dividend
Jubilant Ingrevia reported a mixed Q3 FY26 with revenue declining 1% YoY to ₹1,051 crore and PAT falling 32% to ₹47 crore, largely impacted by a one-time exceptional expense related to labor code amendments and global pricing pressures. Despite the bottom-line hit, the company maintained stable EBITDA margins of 13% and declared an interim dividend of ₹2.5 per share. Management highlighted a robust opportunity funnel of over ₹3,500 crore and the upcoming commencement of a major CDMO order in Q4 FY26. Volume growth across Specialty Chemicals and Nutrition segments helped offset softer global pricing.
Key Highlights
Revenue for Q3 FY26 stood at ₹1,051 crore, a marginal 1% YoY decline due to global pricing pressures.
EBITDA for the quarter was ₹136 crore with a stable margin of 13%, while 9M FY26 EBITDA rose 8% YoY.
The Board declared an interim dividend of 250% amounting to ₹2.5 per equity share.
Specialty Chemicals segment maintained a strong EBITDA margin of 25% despite pricing volatility in Pyridine.
CDMO pipeline expanded to over 100 opportunities with a peak annual revenue potential of ₹3,500 crore.
👀 What to Watch
Investors should monitor the execution of the major CDMO order starting Q4 FY26 and the stabilization of global chemical pricing. While short-term earnings are under pressure, the strong expansion pipeline and dividend payout offer some support for long-term holders.
Jubilant Ingrevia Declares Interim Dividend of Rs 2.50 Per Share; Record Date Feb 10
Jubilant Ingrevia Limited has declared an interim dividend of Rs 2.50 per equity share for the financial year 2025-26. This dividend is applicable to shares with a face value of Re 1 each. The company has designated February 10, 2026, as the record date for identifying eligible shareholders. Shareholders can expect the dividend payment or dispatch to occur on or before March 4, 2026.
Key Highlights
Interim dividend of Rs 2.50 per equity share (250% of face value).
Record date for dividend eligibility set for February 10, 2026.
Dividend payment to be completed on or before March 4, 2026.
Board meeting concluded on February 4, 2026, to approve the payout.
👀 What to Watch
Existing shareholders should ensure they hold the stock before the ex-dividend date to qualify for the Rs 2.50 payout. New investors may consider the dividend yield relative to the current stock price.
Jubilant Ingrevia Declares ₹2.50 Interim Dividend and Re-appoints Independent Director
Jubilant Ingrevia's Board has declared an interim dividend of ₹2.50 per equity share for the financial year 2025-26, representing a 250% payout on the face value of ₹1. The company has fixed February 10, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the board approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 17, 2026. This dual announcement reflects a commitment to both shareholder returns and leadership continuity.
Key Highlights
Interim dividend of ₹2.50 per equity share of ₹1 face value declared for FY 2025-26
Record date for dividend eligibility set for February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Ms. Ameeta Chatterjee re-appointed as Independent Director for a 5-year term until April 2031
Board meeting concluded on February 4, 2026, with all items approved
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date associated with the February 10 record date. The re-appointment of an experienced director like Ms. Chatterjee is a positive sign for corporate governance stability.
Jubilant Ingrevia Declares ₹2.50 Interim Dividend; Sets Feb 10 as Record Date
Jubilant Ingrevia's Board has declared an interim dividend of ₹2.50 per equity share for the financial year 2025-26. The company has fixed February 10, 2026, as the record date to determine eligible shareholders for this payout. Additionally, the Board approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 2026. The dividend is scheduled to be paid or dispatched to shareholders on or before March 4, 2026.
Key Highlights
Interim dividend declared at ₹2.50 per equity share of face value ₹1 each
Record date for dividend eligibility fixed as February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Re-appointment of Ms. Ameeta Chatterjee as Independent Director for a 5-year term until April 2031
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date associated with the Feb 10 record date. The re-appointment of an experienced independent director signals management stability.
Jubilant Ingrevia Declares Rs 2.50 Interim Dividend; Sets Feb 10 as Record Date
Jubilant Ingrevia has declared an interim dividend of Rs 2.50 per equity share for the financial year 2025-26. The company has fixed February 10, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the board has approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 2026. The dividend is scheduled to be paid or dispatched to eligible shareholders by March 4, 2026.
Key Highlights
Interim dividend declared at Rs 2.50 per equity share of Re 1 face value
Record date for dividend eligibility fixed as February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Ms. Ameeta Chatterjee re-appointed as Independent Director for a 5-year term until April 2031
Board meeting concluded at 5:15 PM on February 4, 2026
👀 What to Watch
Investors looking to benefit from the dividend should ensure they hold the stock before the ex-dividend date. The re-appointment of an experienced independent director provides continuity in corporate governance.
Jubilant Ingrevia Declares Rs 2.50 Interim Dividend; Re-appoints Independent Director
Jubilant Ingrevia's Board has declared an interim dividend of Rs 2.50 per equity share for the financial year 2025-26. The company has fixed February 10, 2026, as the record date to identify eligible shareholders for this payout. Additionally, the Board approved the re-appointment of Ms. Ameeta Chatterjee as an Independent Director for a second five-year term starting April 2026. This dual announcement highlights both a commitment to shareholder returns and leadership continuity.
Key Highlights
Interim dividend declared at Rs 2.50 per equity share of Re 1 face value
Record date for dividend eligibility fixed as February 10, 2026
Dividend payment to be completed on or before March 4, 2026
Ms. Ameeta Chatterjee re-appointed as Independent Director for a 5-year term until April 2031
Board meeting concluded on February 4, 2026, at 05:15 p.m.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the record date of February 10, 2026. The re-appointment of an experienced director is a positive sign for corporate governance stability.
Jubilant Ingrevia Q3 FY26 Net Profit Dips 5.6% YoY to ₹65.4 Crore; Revenue Flat
Jubilant Ingrevia reported a consolidated net profit of ₹65.41 crore for Q3 FY26, a 5.6% decline from ₹69.30 crore in the same quarter last year. Revenue from operations remained stagnant at ₹1,050.99 crore compared to ₹1,056.77 crore YoY. Sequentially, the company saw a 6.2% drop in revenue and a 5.8% decline in profit compared to Q2 FY26. Despite the quarterly dip, the nine-month performance remains stronger than the previous year, with PAT up 21% at ₹209.65 crore.
Key Highlights
Consolidated Net Profit for Q3 FY26 stood at ₹65.41 crore vs ₹69.30 crore YoY.
Total Revenue from operations was ₹1,050.99 crore, showing a marginal decline of 0.5% YoY.
Nutrition & Health Solutions segment grew by 5.9% YoY to ₹200.76 crore.
Speciality Chemicals segment revenue declined slightly to ₹457.57 crore from ₹467.64 crore YoY.
Nine-month (9M FY26) PAT increased significantly to ₹209.65 crore from ₹172.90 crore in 9M FY25.
👀 What to Watch
The quarterly results indicate a temporary slowdown in the Speciality Chemicals and Intermediates segments. Investors should hold for long-term recovery while monitoring global chemical pricing trends and margin stability.
Jubilant Foodworks Faces ₹169.59 Crore Income Tax Demand for FY 2021-22
Jubilant Foodworks Limited has received an assessment order from the Income Tax Department for the Financial Year 2021-22, raising a tax demand of ₹169.59 Crores. The demand is primarily related to transfer pricing adjustments and the disallowance of certain expenses, which the company claims are based on mistakes in the record. The company is currently filing for rectification and an appeal before the Income Tax Appellate Tribunal. Management expects the demand to be overturned and does not anticipate any material financial impact on the company's operations.
Key Highlights
Income Tax Department raised a demand of ₹169.59 Crores for FY 2021-22.
The demand involves transfer pricing adjustments and disallowance of specific expenses.
Company is initiating a rectification application and an appeal before the ITAT.
Management believes the order ignores their contentions and expects the demand to be deleted.
No material financial implications are currently anticipated by the company.
👀 What to Watch
Investors should monitor the progress of the tax appeal, as the demand amount is significant. However, given the company's intent to contest and its expectation of no material impact, no immediate action is required.
UBL Launches Kingfisher Super Smooth Strong Beer in Karnataka; Prices Start at INR 100
United Breweries Limited (UBL) has expanded its product portfolio in Karnataka with the launch of Kingfisher Super Smooth Strong Premium Beer on January 28, 2026. This strategic move targets the younger demographic in one of India's largest beer markets, following a successful initial rollout in Rajasthan. The product is priced competitively, ranging from INR 100 for a 330ml can to INR 200 for a 650ml bottle. By offering a smoother strong beer with no added sugar, UBL aims to capture a larger share of the mainstream strong beer segment in urban centers like Bengaluru.
Key Highlights
Launch of Kingfisher Super Smooth Strong Premium Beer in Karnataka effective January 28, 2026
Competitive pricing strategy with 650ml bottles at INR 200 and 500ml cans at INR 155
Strategic focus on younger legal age drinkers in high-consumption urban markets like Bengaluru
Product features imported hops and no added sugar to cater to evolving consumer taste preferences
Expansion follows encouraging early consumer response from the initial launch in Rajasthan
👀 What to Watch
Investors should monitor UBL's volume growth and market share in Karnataka over the next few quarters to assess the success of this premiumization strategy. The launch reinforces UBL's dominant position in the Indian beer market and its ability to innovate within the strong beer segment.
UBL Launches Productivity Program Targeting 3-6% Annualised Savings
United Breweries Limited (UBL) has approved a comprehensive Productivity and Cost Effectiveness Program to counter high taxation and rising raw material costs. The strategy involves a reorganization of business functions, the commissioning of a new Greenfield facility in Uttar Pradesh, and the closure of its Mangalore plant. The company projects that these initiatives will generate sustained annualised savings of 3% to 6%. These gains are intended to be reinvested into brand building and market expansion to drive long-term growth.
Key Highlights
Targeting sustained annualised cost savings of 3% to 6% through operational efficiencies.
Commissioning of a new Greenfield facility in Uttar Pradesh and closure of the Mangalore plant.
Streamlining roles across Sales, Supply Chain, and Logistics to optimize resource allocation.
Rationalization of underperforming SKUs and localization of premium brand production.
Focus on domestic procurement and increased bottle reuse to reduce logistics and material costs.
👀 What to Watch
Investors should view this as a positive move toward margin protection and operational efficiency. Monitor the implementation timeline and the subsequent impact on EBITDA margins over the next 4-6 quarters.
UBL Sells 8-Acre Hyderabad Land for INR 80.8 Crores
United Breweries Limited (UBL) has successfully executed a sale deed for 8 acres of industrial land located in Nacharam, Hyderabad. The transaction was completed for a total consideration of INR 80.8 Crores with Topsun Solar Private Limited. As the land was not being used for any business operations, the sale will have no impact on the company's production capacity or revenue. This move effectively monetizes a non-core asset, providing a significant cash inflow to the company's balance sheet.
Key Highlights
Sale of 8 acres of industrial land in Nacharam, Hyderabad for INR 80.8 Crores
Purchaser identified as Topsun Solar Private Limited, a non-related party
Zero impact on core business operations as the premises were inactive
Transaction executed on January 19, 2026, following Board approval
All stamp duty and registration fees to be borne by the purchaser
👀 What to Watch
Investors should view this as a positive liquidity event that strengthens the balance sheet through the monetization of idle assets. No change in operational guidance is required as the asset was non-performing.
UBL Launches Kingfisher Smooth Strong Beer in Rajasthan; Prices Start at INR 100
United Breweries Limited (UBL) has announced the launch of 'Kingfisher Smooth Strong Premium Beer' in Rajasthan, effective January 07, 2026. This strategic innovation targets the mainstream strong beer segment, which dominates Indian consumption, by offering a smoother taste profile for younger legal-age consumers. The product is competitively priced, with a 650ml bottle at INR 185 and a 500ml can at INR 145. By leveraging Rajasthan, one of India's largest strong beer markets, UBL aims to recruit new consumers into its flagship Kingfisher portfolio.
Key Highlights
Launch of Kingfisher Smooth Strong Premium Beer in Rajasthan on January 07, 2026
Pricing set at INR 100 for 330ml, INR 145 for 500ml cans, and INR 185 for 650ml bottles
Product features imported hops and no added sugar to deliver a balanced, sessionable experience
Strategic focus on the mainstream strong beer segment to attract next-generation consumers
UBL maintains its position as India's largest beer manufacturer under the HEINEKEN Company
👀 What to Watch
Investors should track the volume growth and market share capture in the Rajasthan region following this launch. Success in this 'smooth strong' sub-category could lead to a nationwide rollout, potentially improving margins through product premiumization.
Jubilant Foodworks Q3FY26 Update: Consolidated Revenue Up 13.4%, India LFL Growth at 5.0%
Jubilant Foodworks reported a robust Q3FY26 business update with consolidated revenue growing 13.4% YoY to Rs. 24,387 million. The company's core Domino's India operations recorded a healthy Like-for-Like (LFL) growth of 5.0%, while Turkey operations saw 6.3% LFL growth. Aggressive expansion continued with the addition of 114 net stores globally, including 75 new stores in India alone. This brings the total group network to 3,594 stores, signaling strong market penetration and scale.
Key Highlights
Consolidated revenue from operations increased by 13.4% YoY to Rs. 24,387 million.
Domino's India recorded a positive Like-for-Like (LFL) growth of 5.0% for the quarter.
Net addition of 114 stores across the group network, taking the total count to 3,594.
Domino's India network reached 2,396 stores with 75 new store additions in Q3.
Standalone revenue from operations grew 11.8% YoY to reach Rs. 18,015 million.
👀 What to Watch
The 5% LFL growth in India suggests a recovery in QSR demand; investors should hold for the full earnings report to assess margin impacts from aggressive store expansion.
Jubilant Ingrevia Q2 FY26 Standalone Net Profit Drops 27% YoY to ₹44 Cr; Revenue Up 5%
Jubilant Ingrevia reported a standalone revenue of ₹1,054.18 crore for Q2 FY26, marking a 4.8% increase compared to ₹1,005.39 crore in the same quarter last year. However, net profit witnessed a significant decline of 26.8% YoY, falling to ₹44.03 crore from ₹60.18 crore, primarily due to margin pressure in the Chemical Intermediates segment which reported a loss. While the Speciality Chemicals segment showed robust EBIT growth of 46% YoY, the overall performance was weighed down by an 8% increase in total expenses.
Key Highlights
Standalone Revenue from operations grew 4.8% YoY to ₹1,054.18 crore in Q2 FY26.
Net Profit declined 26.8% YoY to ₹44.03 crore, down from ₹60.18 crore in Q2 FY25.
Speciality Chemicals segment EBIT rose significantly to ₹95.88 crore from ₹65.64 crore YoY.
Chemical Intermediates segment reported an EBIT loss of ₹14.04 crore compared to a profit of ₹30.53 crore in the previous year.
Total expenses increased to ₹1,005.63 crore, driven by higher raw material consumption and power costs.
👀 What to Watch
Investors should remain cautious as the Chemical Intermediates segment has turned loss-making, impacting overall profitability despite growth in Speciality Chemicals. Monitor the company's ability to pass on raw material price increases in upcoming quarters.
Jubilant Foodworks Announces Key Senior Management Changes and New Supply Chain Head
Jubilant Foodworks (JFL) has announced a strategic reshuffle of its senior management team to enhance operational efficiency and long-term growth. Mr. Virender Singh Sehrawat, a veteran with 26 years of experience, joins as EVP & Head of Integrated Supply Chain from Kenvue. Mr. Vibhor Gupta, who previously drove double-digit growth at Domino's India, will now take over as Head of Popeyes. Additionally, Mr. Gaurav Pande will transition into a Corporate Strategy role to focus on identifying future growth opportunities across the business.
Key Highlights
Virender Singh Sehrawat appointed as EVP & Head - Integrated Supply Chain effective December 15, 2025
Vibhor Gupta elevated to Senior Management as EVP & Head - Popeyes effective January 31, 2026
Gaurav Pande transitions to EVP & Head - Corporate Strategy to drive long-term strategic vision
New Supply Chain Head brings 26+ years of experience from Kenvue, Johnson & Johnson, and FMCG sectors
👀 What to Watch
Investors should monitor the scaling of the Popeyes brand and supply chain efficiency improvements under the new leadership. No immediate portfolio action is required as these are planned management transitions.
Jubilant Pharmova Q2 Standalone Revenue Up 8% YoY; Reports Net Loss of ₹64 Million
Jubilant Pharmova reported standalone revenue of ₹664 million for Q2 FY26, an 8% increase from ₹614 million in Q2 FY25. Despite revenue growth, the company posted a net loss of ₹64 million compared to a profit of ₹105 million in the previous year, primarily due to a significant deferred tax charge of ₹551 million. A major structural change was finalized during the quarter with the completion of the API business slump sale to its subsidiary, Jubilant Biosys, on September 1, 2025, which is now accounted for under discontinued operations.
Key Highlights
Standalone revenue from operations grew 8% YoY to ₹664 million in Q2 FY26.
Reported a net loss of ₹64 million for the quarter, heavily impacted by a ₹551 million deferred tax charge.
Profit from discontinued operations (API business) stood at ₹416 million for the quarter.
Completed the slump sale of the Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited on September 1, 2025.
Total standalone assets decreased to ₹23,756 million from ₹29,096 million in March 2025 following the business transfer.
👀 What to Watch
Investors should focus on the consolidated financial performance rather than standalone figures, as the latter are significantly impacted by the internal restructuring and the divestment of the API business. Monitor how the reorganization into Jubilant Biosys affects overall group margins in the coming quarters.
Jubilant Foodworks Receives IT Rectification Order; Tax Demand Reduced to ₹190.21 Cr
Jubilant Foodworks Limited has received a rectification order from the Income Tax Department for the Financial Year 2020-21. The order has led to a reduction in the tax demand from the earlier ₹216.19 Crores to ₹190.21 Crores. The company maintains that the remaining demand is based on ignored contentions and has already filed an appeal against it. Management does not anticipate any material financial implications and expects the demand to be eventually deleted through the redressal process.
Key Highlights
Income Tax demand for FY 2020-21 reduced from ₹216.19 Crores to ₹190.21 Crores
Company has already filed an appeal against the remaining ₹190.21 Crore demand
Management believes the impugned tax demand is likely to be deleted post-redressal
No material financial impact is expected on the company's operations at this stage
👀 What to Watch
Investors should monitor the progress of the tax appeal as the amount involved is significant, though the reduction in demand is a minor positive development. No immediate portfolio changes are recommended based on this routine legal update.
